NASDAQ:VRDN Viridian Therapeutics Q1 2025 Earnings Report $18.92 0.00 (0.00%) Closing price 07/31/2026 04:00 PM EasternExtended Trading$18.92 0.00 (0.00%) As of 07/31/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Viridian Therapeutics EPS ResultsActual EPS-$0.87Consensus EPS -$0.95Beat/MissBeat by +$0.08One Year Ago EPSN/AViridian Therapeutics Revenue ResultsActual Revenue$0.07 millionExpected Revenue$0.16 millionBeat/MissMissed by -$90.00 thousandYoY Revenue GrowthN/AViridian Therapeutics Announcement DetailsQuarterQ1 2025Date5/6/2025TimeBefore Market OpensConference Call DateTuesday, May 6, 2025Conference Call Time7:00AM ETUpcoming EarningsViridian Therapeutics' Q2 2026 earnings is estimated for Wednesday, August 5, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Viridian Therapeutics Earnings HeadlinesViridian Therapeutics (NASDAQ:VRDN) Lowered to "Strong Sell" Rating by Wall Street ZenAugust 1 at 1:12 AM | americanbankingnews.comViridian Therapeutics (VRDN) Rebounds Sharply, Is The Valuation Still Too Rich?July 15, 2026 | finance.yahoo.comIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country. | Banyan Hill Publishing (Ad)Viridian Therapeutics (VRDN) Stock Still Looks Above Fair Value TodayJuly 15, 2026 | finance.yahoo.comWedbush Sees Commercial Edge for Viridian (VRDN) After FDA MilestoneJuly 7, 2026 | finance.yahoo.comViridian Therapeutics, Inc. (VRDN) Discusses FDA Approval and Launch Plans for Lumvoa as a New Therapy for Thyroid Eye Disease - SlideshowJuly 1, 2026 | seekingalpha.comSee More Viridian Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Viridian Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Viridian Therapeutics and other key companies, straight to your email. Email Address About Viridian TherapeuticsViridian Therapeutics (NASDAQ:VRDN) (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders. In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases. Both candidates are being evaluated in multiple clinical trials across North America and Europe, underscoring the company’s commitment to building a robust pipeline of precision biologics. Viridian’s research platform leverages advanced antibody engineering to enhance potency, selectivity and pharmacokinetic properties, supporting the development of differentiated therapies with the potential for best-in-class profiles. Founded in 2020 and headquartered in Boston, Massachusetts, Viridian was established by a team of experienced biotechnology entrepreneurs and scientists. The company completed its initial public offering in 2021 to secure funding for clinical development and manufacturing scale-up. Under the leadership of Chief Executive Officer Mara Aspinall and Chief Medical Officer Michael Rosenzweig, Viridian has formed strategic partnerships with contract development and manufacturing organizations to support its late-stage programs. Viridian’s global footprint extends through clinical sites and collaborative networks aimed at delivering novel treatments to patients worldwide.View Viridian Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Strategy's Structural Strength: Hidden in a $8 Billion IllusionMarketBeat Week in Review – 07/27- 07/31Chevron’s Strong Quarter Shows Why It Still Leads the Energy SectorAbbVie Quietly Solved Its Biggest Problem—Now What?Netflix's Big Sell-Off May Be Sending the Wrong SignalAmazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull CaseApple’s Record Quarter Could Not Outrun Its Guidance Problem Upcoming Earnings Booking (8/3/2026)Marriott International (8/3/2026)Diamondback Energy (8/3/2026)ONEOK (8/3/2026)Williams Companies (8/3/2026)Mitsubishi UFJ Financial Group (8/3/2026)Vertex Pharmaceuticals (8/3/2026)Palantir Technologies (8/3/2026)Spotify Technology (8/4/2026)SpaceX (8/4/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
